In:
Clinical Diabetes, American Diabetes Association, Vol. 36, No. 2 ( 2018-04-01), p. 174-182
Abstract:
IN BRIEF Titratable fixed-ratio combinations (FRCs) of a basal insulin and a glucagon-like peptide-1 (GLP-1) receptor agonist are new therapeutic options for people with type 2 diabetes. Two FRCs—insulin degludec/liraglutide and insulin glargine/lixisenatide—have been approved for use in the United States. The two components in these FRCs target different aspects of diabetes pathophysiology, working in a complementary manner to decrease blood glucose while mitigating the side effects associated with each component (hypoglycemia and weight gain with insulin and gastrointestinal side effects with GLP-1 receptor agonists). This article reviews these products and key considerations for their use.
Type of Medium:
Online Resource
ISSN:
0891-8929
,
1945-4953
Language:
English
Publisher:
American Diabetes Association
Publication Date:
2018
detail.hit.zdb_id:
2001527-6
